Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Teduglutide Syringe vs Pen in Healthy Adults
NCT04465396Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teduglutide in short bowel syndrome (SBS) (4 cohorts), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration, Maximum Observed Plasma Concentration and 1 more. Started Jan 2021; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04465396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465396.